<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mandelker D</submitter><funding>NIDDK NIH HHS</funding><funding>Howard Hughes Medical Institute</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>16996-7001</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2761334</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>106(40)</volume><pubmed_abstract>Mutations in oncogenes often promote tumorigenesis by changing the conformation of the encoded proteins, thereby altering enzymatic activity. The PIK3CA oncogene, which encodes p110alpha, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kalpha), is one of the two most frequently mutated oncogenes in human cancers. We report the structure of the most common mutant of p110alpha in complex with two interacting domains of its regulatory partner (p85alpha), both free and bound to an inhibitor (wortmannin). The N-terminal SH2 (nSH2) domain of p85alpha is shown to form a scaffold for the entire enzyme complex, strategically positioned to communicate extrinsic signals from phosphopeptides to three distinct regions of p110alpha. Moreover, we found that Arg-1047 points toward the cel</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.</pubmed_title><pmcid>PMC2761334</pmcid><funding_grant_id>T32 GM007184</funding_grant_id><funding_grant_id>CA43460</funding_grant_id><funding_grant_id>T32 GM007309</funding_grant_id><funding_grant_id>GM07309</funding_grant_id><funding_grant_id>P30 DK079637</funding_grant_id><funding_grant_id>R37 CA043460</funding_grant_id><funding_grant_id>GM07184</funding_grant_id><pubmed_authors>Gabelli SB</pubmed_authors><pubmed_authors>Cheong I</pubmed_authors><pubmed_authors>Kinzler KW</pubmed_authors><pubmed_authors>Mandelker D</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Vogelstein B</pubmed_authors><pubmed_authors>Schmidt-Kittler O</pubmed_authors><pubmed_authors>Huang CH</pubmed_authors><pubmed_authors>Amzel LM</pubmed_authors></additional><is_claimable>false</is_claimable><name>A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.</name><description>Mutations in oncogenes often promote tumorigenesis by changing the conformation of the encoded proteins, thereby altering enzymatic activity. The PIK3CA oncogene, which encodes p110alpha, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kalpha), is one of the two most frequently mutated oncogenes in human cancers. We report the structure of the most common mutant of p110alpha in complex with two interacting domains of its regulatory partner (p85alpha), both free and bound to an inhibitor (wortmannin). The N-terminal SH2 (nSH2) domain of p85alpha is shown to form a scaffold for the entire enzyme complex, strategically positioned to communicate extrinsic signals from phosphopeptides to three distinct regions of p110alpha. Moreover, we found that Arg-1047 points toward the cel</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009 Oct</publication><modification>2026-05-05T04:46:25.801Z</modification><creation>2019-03-27T00:25:51Z</creation></dates><accession>S-EPMC2761334</accession><cross_references><pubmed>19805105</pubmed><doi>10.1073/pnas.0908444106</doi></cross_references></HashMap>